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Abstract. 
 
Integrin 
 
a
 
IIb
 
b
 
3
 
 mediates platelet aggregation 
and “outside-in” signaling. It is regulated by changes in 
receptor conformation and affinity and/or by lateral 
diffusion and receptor clustering. To document the rel-
ative contributions of conformation and clustering to 
 
a
 
IIb
 
b
 
3
 
 function, 
 
a
 
IIb
 
 was fused at its cytoplasmic tail to 
one or two FKBP12 repeats (FKBP). These modified 
 
a
 
IIb
 
 subunits were expressed with 
 
b
 
3
 
 in CHO cells, and 
the heterodimers could be clustered into morphologi-
cally detectable oligomers upon addition of AP1510, a 
membrane-permeable, bivalent FKBP ligand. Integrin 
clustering by AP1510 caused binding of fibrinogen and 
a multivalent (but not monovalent) fibrinogen-mimetic 
antibody. However, ligand binding due to clustering 
was only 25–50% of that observed when 
 
a
 
IIb
 
b
 
3
 
 affinity 
was increased by an activating antibody or an activating 
mutation. The effects of integrin clustering and affinity 
modulation were additive, and clustering promoted ir-
reversible ligand binding. Clustering of 
 
a
 
IIb
 
b
 
3
 
 also pro-
moted cell adhesion to fibrinogen or von Willebrand 
factor, but not as effectively as affinity modulation. 
However, clustering was sufficient to trigger fibrino-
gen-independent tyrosine phosphorylation of pp72
 
Syk
 
 
and fibrinogen-dependent phosphorylation of 
pp125
 
FAK
 
, even in non-adherent cells. Thus, receptor 
clustering and affinity modulation
 
 
 
play complementary 
roles in 
 
a
 
IIb
 
b
 
3
 
 function. Affinity modulation is the pre-
dominant regulator of ligand binding and cell adhesion, 
but clustering increases these responses further and 
triggers protein tyrosine phosphorylation, even in the 
absence of affinity modulation. Both affinity modula-
tion and clustering
 
 
 
may be needed for optimal function 
of 
 
a
 
IIb
 
b
 
3
 
 in platelets.
 
I
 
ntegrins
 
 are type I transmembrane 
 
ab
 
 heterodimers
that mediate cell adhesion and signaling in a highly
regulated manner (Clark and Brugge, 1995). Several
modes of integrin regulation have been demonstrated or
postulated, including control of expression on the cell sur-
face by coordinate subunit biosynthesis and recycling
(Bennett, 1990; Bretscher, 1992), modulation of receptor
affinity by conformational changes in the heterodimer
(Sims et al., 1991; Shattil et al., 1998), and modulation of
receptor avidity by lateral diffusion of heterodimers to
form higher order multimers or clusters (Detmers et al.,
1987; van Kooyk et al., 1994; Kucik et al., 1996; Bazzoni
and Hemler, 1998). The latter process may be promoted
by interactions of integrins with multivalent, extracellular
ligands (Peerschke, 1995
 
b
 
; Simmons et al., 1997), and with
components of the dynamic actin cytoskeleton (Sastry and
Horwitz, 1993; Fox et al., 1996; Kucik et al., 1996). Integrin
function must sometimes be regulated acutely over sec-
onds to minutes to enable the kinds of rapid changes in
cell adhesion and migration that are required during im-
mune responses, inflammation, and hemostasis. Several
integrins in blood cells are targets of this type of activation
or “inside-out” signaling, including 
 
a
 
4
 
b
 
1
 
, 
 
a
 
L
 
b
 
2
 
, and 
 
a
 
M
 
b
 
2
 
 in
leukocytes, and 
 
a
 
IIb
 
b
 
3 
 
and 
 
a
 
V
 
b
 
3
 
 in platelets (Bennett et al.,
1997; Bazzoni and Hemler, 1998; Shattil et al., 1998). It
seems likely that some combination of conformational
change and receptor clustering is involved in activating the
ligand-binding function of these integrins. However, evi-
dence to support one or the other mechanism has been
largely indirect, and it has been difficult to determine the
relative contributions of each in intact cells. The distinc-
tion between integrin affinity and avidity modulation is
not academic because the underlying mechanisms may be
different, with implications for therapeutic strategies to
block or promote integrin functions in pathological condi-
tions (Coller, 1997; Bazzoni and Hemler, 1998).
One of the best-studied integrins from the standpoint of
acute regulation is 
 
a
 
IIb
 
b
 
3
 
, which interacts with Arg-Gly-
Asp–containing ligands, such as fibrinogen and von Wille-
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brand factor (vWf),
 
1
 
 to effect platelet aggregation and
spreading on vascular surfaces. Platelet agonists, such as
thrombin and ADP, cause rapid changes in the adhesive
function of 
 
a
 
IIb
 
b
 
3
 
, as evidenced by increases in the binding
of soluble fibrinogen, vWf, and ligand-mimetic mAbs, in-
cluding PAC1 (Shattil et al., 1985). Antagonists, such as
prostacyclin and nitric oxide can inhibit and, under some
conditions reverse these acute changes (Graber and Ha-
wiger, 1982; Freedman et al., 1997). Coupled with evidence
from fluorescence resonance energy transfer studies show-
ing that the 
 
a
 
IIb
 
 and 
 
b
 
3
 
 subunits undergo changes in rela-
tive orientation during platelet activation (Sims et al., 1991),
a current hypothesis is that ligand binding to 
 
a
 
IIb
 
b
 
3 
 
is con-
trolled, at least in part, by changes in heterodimer confor-
mation that affect access of the ligand to recognition sites
in the receptor (Loftus and Liddington, 1997; Shattil et al.,
1998). On the other hand, it is entirely possible that cluster-
ing of 
 
a
 
IIb
 
b
 
3 
 
also occurs during the process of platelet activa-
tion. Indeed, clustering of 
 
a
 
IIb
 
b
 
3
 
 on the platelet surface has
been detected by electron microscopy after ligand binding
(Isenberg et al., 1987; Simmons et al., 1997). Were clustering
to occur directly in response to platelet agonists, it could en-
hance ligand binding through chelate and rebinding effects.
Furthermore, “outside-in” signaling through 
 
a
 
IIb
 
b
 
3
 
, mani-
fested by activation of specific protein tyrosine kinases, lipid
kinases, and cytoskeletal reorganization (Fox et al., 1993;
Banfic et al., 1998; Shattil et al., 1998), seems to require the
binding of multivalent ligands (Huang et al., 1993), indirectly
suggesting a functional role for
 
 
 
oligomerization of 
 
a
 
IIb
 
b
 
3
 
.
Since platelets are not amenable to genetic manipula-
tions ex vivo, heterologous expression systems have been
used to study the structure and function of 
 
a
 
IIb
 
b
 
3
 
 (O’Toole
et al., 1994; Loh et al., 1996). For example, human 
 
a
 
IIb
 
b
 
3
 
expressed in CHO cells binds little or no fibrinogen or
PAC1 and is therefore, in a constitutively low affinity/
avidity state, just as it is in resting platelets. However, the
affinity of 
 
a
 
IIb
 
b
 
3
 
 can be increased by incubation of the cells
with particular “LIBS” mAb Fab fragments that bind to
the 
 
a
 
 or 
 
b
 
 integrin subunit and induce a conformational
change in the extracellular portion of the receptor to ex-
pose ligand binding sites (O’Toole et al., 1994). Under
these experimental conditions, monovalent LIBS Fab frag-
ments by themselves would not be expected to induce re-
ceptor clustering. In the present study, we have used new
modifications of this experimental system to establish the
separate contributions of affinity modulation and receptor
clustering to the functions of 
 
a
 
IIb
 
b
 
3
 
. Specifically, single or
tandem repeats of the FK506-binding protein, FKBP12
(FKBP), have been fused to the cytoplasmic tail of 
 
a
 
IIb
 
 to
conditionally cluster heterodimers
 
 
 
into oligomers from in-
side the cell using AP1510, a synthetic, bivalent, and mem-
brane-permeable FKBP dimerizer (Amara et al., 1997).
The results establish that affinity modulation and receptor
clustering can play complementary roles in the adhesive
and signaling functions of this prototypic integrin. Whereas
affinity modulation is the predominant mechanism for reg-
ulating ligand binding to 
 
a
 
IIb
 
b
 
3
 
, receptor clustering facili-
tates this process and promotes outside-in signaling, even
in the absence of affinity modulation.
 
Materials and Methods
 
Plasmid Constructions and Expression of Recombinant 
Forms of 
 
a
 
IIb
 
b
 
3
 
 in CHO Cells
 
A pCDM8 template containing full-length 
 
a
 
IIb
 
 (O’Toole et al., 1994) was
subjected to PCR with 
 
Pfu
 
 polymerase (Stratagene, La Jolla, CA) to place
XbaI and SpeI restriction sites at the 5
 
9
 
 and 3
 
9
 
 ends of 
 
a
 
IIb
 
, respectively.
The PCR product was cut with XbaI and SpeI and ligated into an XbaI-cut,
CMV-based mammalian expression vector, pCF1E (ARIAD Pharmaceu-
tical, Inc., Cambridge, MA). Plasmids with inserts in the correct orienta-
tion were amplified and purified for CHO cell transfections (Maxi-Prep;
QIAGEN Inc., Chatsworth, CA). The resulting 
 
a
 
IIb
 
(FKBP)/pCF1E plas-
mid encoded 
 
a
 
IIb
 
 fused in-frame to FKBP, which in turn was fused in-
frame to a hemagglutinin epitope tag (see Fig. 1). To construct 
 
a
 
IIb
 
 fused
to two tandem FKBP repeats (
 
a
 
IIb
 
(FKBP)
 
2
 
), a single FKBP was removed
from pCF1E with XbaI/SpeI and ligated into SpeI-cut 
 
a
 
IIb
 
(FKBP)/pCF1E.
The remaining 
 
a
 
IIb
 
 and 
 
b
 
3 
 
cDNAs depicted in Fig. 1 were in pCDM8
(O’Toole et al., 1994). cDNA coding full-length human Syk was in EMCV
(Gao et al., 1997). Plasmid inserts were analyzed by automated sequenc-
ing to confirm authenticity.
cDNAs were transfected into CHO-K1 cells with lipofectamine accord-
ing to the manufacturer’s instructions (GIBCO BRL, Gaithersburg, MD).
Typically, 0.5–2 
 
m
 
g of each plasmid was used, supplemented when neces-
sary with empty vector DNA (pCDNA3; Invitrogen, San Diego, CA) for a
total of 4 
 
m
 
g per dish. Cells were maintained for 48 h for transient expres-
sion or subjected to antibiotic selection for stable expression. Stable cell lines
were selected further for high integrin expression by single cell FACS
 
®
 
sorting using an 
 
a
 
IIb
 
b
 
3
 
-specific murine mAb, D57 (O’Toole et al., 1994).
 
Characterization of Recombinant Integrins in
CHO Cells
 
Cell surface expression of recombinant 
 
a
 
IIb
 
b
 
3
 
 was assessed by flow cytom-
etry using biotin-D57 and FITC-streptavidin (Leong et al., 1995). 
 
a
 
IIb
 
 ex-
pression was also evaluated by Western blotting. 48 h after transfection,
the cells were lysed in 66 mM Tris-HCl, pH 7.4, containing 2% SDS and
30 
 
m
 
g of protein were electrophoresed in SDS–7.5% polyacrylamide gels
under nonreducing conditions, transferred to nitrocellulose, and then sub-
jected to Western blotting with murine mAb B1B5 specific for 
 
a
 
IIb
 
 or anti-
body 12CA5 specific for the hemagglutinin epitope tag (Abrams et al.,
1992). After addition of affinity-purified, HRP-conjugated goat anti–
mouse IgG (Biosource International, Camarillo, CA), blots were devel-
oped for 0.1–1 min by enhanced chemiluminescence (ECL; Amersham,
Arlington Heights, IL).
 
Confocal Microscopy
 
To establish whether AP1510 could induce clustering of 
 
a
 
IIb
 
(FKBP)
 
2
 
b
 
3
 
that was detectable morphologically, cells stably expressing 
 
a
 
IIb
 
(FKBP)
 
2
 
b
 
3
 
were incubated in the presence of 1,000 nM AP1510 (or 0.5% EtOH as a
vehicle control) for 30 min at room temperature. Then, analogous to the
method used by Yauch and co-workers to detect antibody-induced inte-
grin clustering (Yauch et al., 1997), the cells were incubated with 10%
goat serum for 30 min at room temperature, followed by 10 
 
m
 
M FITC-
D57 or unlabeled D57 for 30 min on ice. After washing, the sample con-
taining unlabeled D57 was incubated for 30 min with FITC-labeled goat
anti–mouse heavy and light chains (1:500; Biosource International) to de-
liberately cluster the integrin as a positive control. All samples were fixed
in 4% paraformaldehyde, resuspended in mounting medium (Fluorosave;
Calbiochem-Novabiochem, San Diego, CA), and analyzed on glass slides
with an MRC 1024 laser scanning confocal imaging system (Bio-Rad Lab-
oratories, Hercules, CA).
 
Measurements of Ligand Binding Due to Clustering and 
Affinity Modulation of 
 
a
 
IIb
 
b
 
3
 
Ligand binding to 
 
a
 
IIb
 
b
 
3 
 
in CHO cells was assessed by flow cytometry us-
ing a saturating amount of the fibrinogen-mimetic, murine monoclonal
IgMk antibody, PAC1 (Kashiwagi et al., 1997). CHO cells were resus-
pended to 107 cells/ml in Tyrode’s buffer supplemented with 2 mM CaCl2 and
MgCl2 (O’Toole et al., 1994). For most experiments, 4 3 105 cells were
added to tubes containing a final concentration of 0.4% PAC1 ascites or
40 nM purified PAC1 in a final vol of 50 ml, and then incubated for 30 min
1. Abbreviations used in this paper: ECL, enhanced chemiluminescence;
FKBP, FK506 binding protein, or FKBP12; vWf, von Willebrand factor.Hato et al. Integrin Clustering and Conformation 1687
at room temperature. In some experiments, monovalent recombinant
PAC1 Fab produced in insect cells and purified by nickel-agarose chroma-
tography was used instead of PAC1 IgM at a final concentration of 30 nM
(Abrams et al., 1994). As indicated for each experiment, cell incubations
were also carried out in the presence of one or more of the following re-
agents: 10–5,000 nM AP1510 (or vehicle buffer) to cluster aIIb(FKBP)2b3
or aIIb(FKBP)b3 (Amara et al., 1997), 150 mg/ml anti-LIBS6 Fab to con-
vert aIIbb3 into a high affinity form through conformational changes (Du
et al., 1993; Kashiwagi et al., 1997), and 10 mM integrilin, an aIIbb3 antago-
nist to specifically block PAC1 binding (Scarborough et al., 1993). Prelim-
inary experiments with AP1510 and anti–LIBS6 Fab indicated that a 10–
30-min incubation of cells with these reagents was sufficient to achieve
their maximum effects. Cells were then washed and incubated on ice for
30 min with biotin-D57, followed by phycoerythrin-streptavidin and either
FITC-labeled goat anti–mouse m heavy chain antibody (to label PAC1
IgM) or FITC-labeled goat anti–mouse heavy and light chain antibody (to
label PAC1 Fab) (both from Biosource International). Samples were di-
luted with 0.5 ml Tyrode’s buffer containing 2 mg/ml propidium iodide
(Sigma Chemical Co., St. Louis, MO) and analyzed on a FACSCalibur®
flow cytometer (Becton Dickinson Co., Mountain View, CA). After elec-
tronic compensation, PAC1 binding (FL1 channel) was analyzed on the
gated subset of live cells (propidium iodide–negative, FL3) that was posi-
tive for aIIbb3 expression (FL2). To control for variations in integrin ex-
pression from transfection to transfection, PAC1 binding, measured as
mean fluorescence intensity in arbitrary units, was expressed relative to
the levels of aIIbb3, measured simultaneously with biotin-D57.
Adhesion of CHO Cells to Fibrinogen and vWF
Immulon-2 microtiter wells (Dynex Laboratories, Chantilly, VA) were
coated with purified fibrinogen (Enzyme Research Laboratories, South
Bend, IN) or vWf (Ruggeri et al., 1983) overnight at 48C at coating con-
centrations ranging from 0.01–2 mg/well, followed by blocking with 20 mg/ml
BSA. CHO cells stably expressing aIIb(FKBP)2b3 were labeled for 30 min
at 378C with 2 mM BCECF-AM (Molecular Probes, Eugene, OR). After
washing, the cells were resuspended to 106/ml, incubated for 30 min in the
presence of 1,000 nM AP1510 and/or 150 mg/ml anti–LIBS6 Fab, and then
100-ml aliquots were added to the coated microtitre wells for 90 min at
378C. After washing three times with 150 ml of PBS, cell adhesion was
quantitated by cytofluorimetry (Leng et al., 1998).
Protein Tyrosine Phosphorylation in CHO Cells
Stable cell lines expressing aIIb(FKBP)2b3 were transiently transfected
with EMCV-Syk and placed into complete DME with 10% FBS. 24 h af-
ter transfection, the amount of serum was reduced to 0.5%, and 48 h after
transfection, the cells were resuspended to 3 3 106/ml in DME and slowly
rotated at 378C for 45 min in the presence of 20 mM cycloheximide. Then
cells were incubated for 10 min with one or more of the following: 1,000
nM AP1510 to stimulate receptor clustering, 150 mg/ml anti–LIBS6 Fab to
increase integrin affinity, or 250 mg/ml fibrinogen to achieve ligand binding.
As a positive tyrosine phosphorylation control, one aliquot of cells was al-
lowed to attach for 60 min to a dish coated with aIIbb3 antibody D57. Cells
were lysed in RIPA buffer containing 1% Triton X-100, 1% sodium deox-
ycholate, 0.1% SDS, 158 mM NaCl, 10 mM Tris, pH 7.4, 1 mM Na2EGTA,
0.5 mM leupeptin, 0.25 mg/ml Pefabloc, 5 mg/ml aprotinin, 20 mM NaF, 3 mM
b-glycerophosphate, 10 mM sodium pyrophosphate, and 5 mM sodium van-
adate. After clarification, 200 mg of protein were immunoprecipitated
with rabbit antiserum specific for Syk or FAK (Gao et al., 1997). Immuno-
precipitates were subjected to Western blotting with anti-phosphotyrosine
mAbs, 4G10, and PY20 (Upstate Biotechnology Inc., Lake Placid, NY
and Transduction Laboratories, Lexington, KY, respectively), followed by
stripping and reprobing with mAb 4D10 to Syk or antiserum to FAK
(Gao et al., 1997). Immunoreactive bands detected by ECL were quanti-
tated by calibrated densitometry using a flatbed scanner, Power Center
Pro 240 computer, and NIH Image software.
Results
Heterologous Expression of aIIbb3 Containing 
Dimerization Motifs
The purpose of these studies was to evaluate the possible
contributions of integrin clustering and affinity modula-
tion to the adhesive and signaling functions of aIIbb3. A
CHO cell model system, previously used to study factors
that influence the ligand-binding affinity of human aIIbb3
(O’Toole et al., 1994; Hughes et al., 1996; Zhang et al.,
1996; Kashiwagi et al., 1997), has now been adapted to
study integrin clustering. Full-length aIIb was engineered
to contain one or two FKBP repeats and a hemagglutinin
epitope tag at the extreme COOH terminus of the cyto-
plasmic tail (Fig. 1). In theory, a protein containing a sin-
gle FKBP may dimerize upon addition of a membrane-
permeable, bivalent FKBP ligand, such as AP1510, and a
protein with two or more FKBP repeats may form larger
oligomers (Amara et al., 1997; Yap et al., 1997; Yang et al.,
1998). Consequently, we reasoned that if aIIb(FKBP) or
aIIb(FKBP)2 were successfully coexpressed on the surface
of CHO cells along with b3, then aIIbb3 heterodimers might
be converted into a dimer of dimers ((aIIbb3)2) or into
even larger oligomers in response to AP1510.
After transient or stable expression in CHO cells, both
aIIb(FKBP)b3 and aIIb(FKBP)2b3 were found to be ex-
pressed to the same extent as wild-type aIIbb3, as deter-
mined by the binding of D57, an aIIbb3-specific antibody
(Fig. 2 A). In addition, Western blotting of the cell lysates
with an antibody specific for the extracellular domain of
aIIb (B1B5) showed that aIIb(FKBP) and aIIb(FKBP)2 ex-
hibited the predicted slower electrophoretic mobilities
compared with the smaller wild-type aIIb subunit (Fig. 2
B). The aIIb(FKBP) and aIIb(FKBP)2 fusion proteins also
reacted on Western blots with an antibody to the COOH-
terminal epitope tag, further suggesting that they repre-
sented full-length proteins (Fig. 2 B). Thus, the fusion of
one or two FKBP repeats to the cytoplasmic tail of aIIb
does not interfere with the transient or stable expression
of this subunit in CHO cells to form an aIIbb3 complex.
Therefore, in the following studies transient and stable cell
lines were used as indicated, depending on the experimen-
tal protocol.
Conditional Clustering of aIIbb3 in CHO Cells
Large integrin oligomers might be detectable in CHO cells at
the level of light microscopy (van Kooyk et al., 1994; Yauch
et al., 1997). To determine if clusters of aIIb(FKBP)2b3 could
Figure 1. Integrin constructs used in this study. The vertical bar
represents the cell membrane. Integrin extracellular domains are
to the left of the bar and intracellular domains to the right. The
relative sizes of the various domains are not drawn to scale. For
example, the cytoplasmic tail of aIIb contains 20 amino acid resi-
dues and a single FKBP repeat contains z100 residues. The as-
terisk in b3(S752P) marks the site of the point mutation.The Journal of Cell Biology, Volume 141, 1998 1688
be detected morphologically, CHO cells stably expressing
  this integrin were incubated for 30 min at room tempera-
ture with 1,000 nM AP1510 (or vehicle buffer as a control),
stained with FITC-D57 on ice, fixed, and then examined
by confocal microscopy. D57 staining was entirely surface
associated, and cells that had been treated with buffer in-
stead of AP1510 exhibited a finely patchy distribution of
aIIb(FKBP)2b3 (Fig. 3, A–C). In contrast, aIIb(FKBP)2b3 in
cells treated with AP1510 exhibited a coarse patchiness
(Fig. 3, E–G), similar to that observed when the D57 anti-
body was deliberately cross-linked with a secondary antibody
before cell fixation (Fig. 3 H). The same results with AP1510
were obtained with another independent aIIb(FKBP)2b3
clone; in contrast, AP1510 caused no discernible clustering
of wild-type aIIbb3 in CHO cells (not shown). These results
are consistent with the conclusion that oligomerization of
aIIb(FKBP)2b3 can be induced conditionally from within
the cell using AP1510, enabling us to conduct a detailed
study of the functional consequences of integrin clustering.
Receptor Clustering in the Regulation of Ligand 
Binding to aIIbb3
Activation of aIIbb3 is required for the binding of soluble,
macromolecular Arg-Gly-Asp–containing ligands, such as
fibrinogen, vWf, and fibrinogen-mimetic antibodies, such
as PAC1. To evaluate the contribution of clustering to
aIIbb3 activation, flow cytometry was used to quantitate
the specific binding of PAC1 to transiently transfected
CHO cells. Specific binding was defined as that inhibitable
by 10 mM integrilin, an aIIbb3-selective antagonist, and it
was expressed relative to the amount of aIIbb3 on the cell
surface, determined simultaneously with antibody D57. In
cells expressing aIIb(FKBP)2b3, there was little binding of
PAC1, indicating that, like aIIbb3, this integrin is in a con-
stitutive low affinity/avidity state. AP1510 caused a dose-
dependent increase in PAC1 binding to aIIb(FKBP)2b3
cells (Fig. 4, closed circles), without affecting the levels of
surface expression of this integrin. However, PAC1 bind-
ing due to AP1510 appeared modest compared with bind-
ing in response to upregulation of integrin affinity by an
activating antibody Fab fragment, anti–LIBS6 Fab (Fig. 4,
open circles).
To evaluate possible mechanistic differences between
integrin clustering and affinity modulation in the control
of ligand binding, additional experiments were performed
with cells expressing aIIb(FKBP)2b3. First, we considered
the possibility that AP1510 caused PAC1 binding by in-
creasing integrin affinity rather than (or in addition to)
avidity. However, AP1510 failed to stimulate the binding
of a monovalent PAC1 Fab fragment to aIIb(FKBP)2b3, al-
though this form of PAC1 bound normally in response to
anti–LIBS6 Fab (Fig. 5). Since a monovalent ligand might
be expected to be sensitive to affinity modulation but less
sensitive than a multivalent ligand to avidity modulation,
this result suggests that AP1510 was indeed working by
clustering the integrin. Second, PAC1 binding in response
to AP1510 was completely prevented if the cells were pre-
incubated for 30 min with 4 mg/ml of 2-deoxy-d-glucose
and 0.2% sodium azide to deplete metabolic ATP (two
separate experiments). Since oligomerization by AP1510
should be energy independent, this suggests that metabolic
energy is needed to maintain the receptor in a proper con-
formation, even when ligand binding is triggered by recep-
tor clustering. Third, the effect of a specific point mutation
(b3(S752P)) or a truncation (b3(D724)) of the b3 cytoplas-
mic tail were studied because both have been shown to
Figure 2. Expression of
aIIb(FKBP)  fusion constructs
with b3 in CHO cells. In A,
cells were transiently or sta-
bly transfected with the indi-
cated integrin subunits and
stained with a combination
of the anti-aIIbb3 mAb, bi-
otin-D57, and FITC-streptavidin for assessment of integrin sur-
face expression by flow cytometry. One sample of cells was mock
transfected to serve as a negative control in the transient transfec-
tions, and untransfected CHO cells served as a negative control
for the stable transfectants. In B, cells were transiently trans-
fected with the indicated integrin constructs. 48 h later, the cells
were lysed with SDS sample buffer and 30 mg of protein were sub-
jected to Western blotting with an mAb to aIIb (B1B5) or anti-
body 12CA5 to the hemagglutinin epitope tag located at the
COOH terminus of aIIb(FKBP) and aIIb(FKBP)2. Brackets indi-
cate the region on each blot where the different forms of aIIb are
located. The very light band seen in the CHO cell lane on the
B1B5 blot was neither consistent nor specific. In this particular
experiment, the level of expression of aIIb(FKBP)2b3 was less than
that of aIIb(FKBP)b3, accounting for the difference in band inten-
sities between the two samples.Hato et al. Integrin Clustering and Conformation 1689
disrupt affinity modulation of aIIbb3 in platelets and CHO
cells (Chen et al., 1992, 1994; O’Toole et al., 1994; Wang
et al., 1997). Whereas b3(S752P) abolished PAC1 binding
in response to AP1510, b3(D724) had no such effect (Fig.
6). Thus the b3 cytoplasmic tail plays a role in ligand bind-
ing triggered by integrin clustering, but there must be dif-
ferences in the structural features of b3 required for affin-
ity and avidity modulation.
Thus far, the results support the validity of this model
system to study integrin clustering, and they suggest that
both clustering and affinity modulation can regulate ligand
binding to aIIbb3. Further studies were performed to deter-
mine the relative contributions of clustering and affinity
modulation to ligand binding under conditions in which
the effects of AP1510 and anti–LIB6 Fab were maximal
(1,000 nM and 150 mg/ml, respectively). CHO cells were
transiently transfected with either aIIbb3, aIIb(FKBP)b3,
aIIb(FKBP)2b3, or aIIb/a6Ab3 (a constitutive, high affinity
mutant [O’Toole et al., 1994]), and ligand binding was
evaluated 48 h later. Whereas AP1510 had no effect on
PAC1 binding to wild-type aIIbb3, it increased binding to
both aIIb(FKBP)b3 and aIIb(FKBP)2b3 such that specific
PAC1 binding was increased approximately twofold (P ,
0.001) (Fig. 7). However, PAC1 binding induced by AP1510
amounted to only 50% of the binding observed with the
high affinity aIIb/a6Ab3 chimera, and only 25% of the bind-
ing induced by anti–LIBS6 Fab (Fig. 7). Nevertheless, the
PAC1 binding caused by clustering was statistically signifi-
cant (P , 0.03) and approximately additive to the binding
caused by affinity modulation (Fig. 7).
Fibrinogen and PAC1 binding to activated platelets is
initially reversible by the addition of EDTA, but binding
becomes progressively irreversible over 15–60 min (Peer-
schke, 1995a; Fox et al., 1996). In CHO cells that expressed
aIIb(FKBP)2b3 and were treated with both anti–LIBS6 Fab
and AP1510 to achieve maximal PAC1 binding, the added
component of ligand binding resulting from AP1510 was
fully reversible at 10 min but irreversible at 30 min (Fig. 8).
Similar results were obtained when FITC-fibrinogen was
used instead of PAC1 to monitor ligand binding (not
shown). This series of experiments demonstrates that af-
finity modulation is the predominant regulator of ligand
binding to aIIbb3. However, receptor clustering plays an
additive role in promoting eventual irreversible binding of
the ligand.
aIIbb3 Clustering in the Regulation of Cell Adhesion
Activation of platelets by agonists leads to increased cell
adhesion to the aIIbb3 ligands, fibrinogen, and vWf (Sav-
age et al., 1992). To determine the relative contributions of
aIIbb3 clustering and affinity modulation to cell adhesion,
CHO cells that stably expressed aIIb(FKBP)2b3 were
loaded with BCECF as a fluorescent marker and incubated
for 90 min in microtiter wells coated with fibrinogen or vWf.
Cell adhesion was dependent on the coating concentration
of fibrinogen (Fig. 9, left panel) and vWf (Fig. 9, right
panel), as well as on the presence of aIIb(FKBP)2b3, since
it was blocked by 10 mM integrilin. AP1510 (1,000 nM) in-
creased the extent of cell adhesion, but only very modestly
and only at the higher coating concentrations of fibrinogen
and vWf. On the other hand, increasing integrin affinity
with anti–LIBS6 Fab (150 mg/ml) caused a more marked
increase in cell adhesion, even at the lower ligand concen-
trations (Fig. 9, left and right panels). Thus under these as-
say conditions, receptor clustering is not as effective as af-
finity modulation in regulating cell adhesion via aIIbb3.
aIIbb3 Clustering in the Regulation of
Outside-In Signaling
In platelets and CHO cell transfectants, fibrinogen binding
to aIIbb3 leads to tyrosine phosphorylation and activation
Figure 3. Distribution of
aIIb(FKBP)2b3 in CHO cells.
CHO cells stably expressing
aIIb(FKBP)2b3 were incubated
in suspension for 30 min in the
absence (A–D, and H) or pres-
ence (E–G) of 1,000 nM AP1510.
They were then incubated at 48C
with FITC-D57 to stain the inte-
grin (A–C, and E–G), fixed, and
then deposited onto glass slides
for confocal microscopy. As a
negative control, cells in D were
incubated only with FITC goat
anti–mouse immunoglobulin. As
a positive control, cells in H
were incubated with unlabeled
D57, followed by FITC goat
anti–mouse immunoglobulin to
deliberately cross-link the inte-
grin before fixation. Panels rep-
resent single images collected
from the entire series of 0.5-mm
focal planes. Images are from a
single experiment representative
of four so performed. Bar, 10 mm.  
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of Syk and FAK. The binding of soluble fibrinogen is suffi-
cient to activate Syk, but additional post–ligand binding
events, such as cytoskeletal reorganization, are necessary
for activation of FAK (Huang et al., 1993; Clark et al.,
1994; Gao et al., 1997). To study the role of integrin cluster-
ing in these events, CHO cells stably expressing 
 
a
 
IIb
 
(FKBP)
 
2
 
b
 
3
 
were transiently-transfected with human Syk, and tyrosine
phosphorylation of Syk and endogenous hamster FAK
was examined. Fig. 10 
 
A
 
 shows the raw data for a single
experiment and Fig. 10 
 
B
 
 shows a summary of three sepa-
rate experiments. Cells maintained in suspension for 10
min in the absence or presence of fibrinogen exhibited a
low level of tyrosine phosphorylation of Syk and FAK.
However, addition of 1,000 nM AP1510 caused an average
2.8-fold increase in tyrosine phosphorylation of Syk, even
in the absence of fibrinogen (
 
P
 
 
 
, 
 
0.05), and this response
was greater still in the presence of fibrinogen (5.4-fold;
 
P 
 
, 
 
0.02). In contrast, in the absence of fibrinogen inte-
grin clustering by AP1510 did not stimulate an increase in
FAK tyrosine phosphorylation, but increased FAK phos-
phorylation was observed in the presence of fibrinogen
(3.5-fold;
 
 P 
 
, 
 
0.001). Thus, integrin clustering can trigger
tyrosine phosphorylation of Syk even in the absence of fi-
brinogen binding, whereas phosphorylation of FAK re-
quires both receptor clustering and fibrinogen binding. Af-
finity modulation by anti-LIBS6 is not necessary in either
case.
 
Discussion
 
In this study, engraftment of one or two FKBP repeats
onto the COOH terminus of the 
 
a
 
IIb
 
 subunit enabled us to
cluster integrin 
 
a
 
IIb
 
b
 
3
 
 in a conditional fashion by treating
CHO cells with a synthetic, bivalent FKBP ligand, AP1510.
This permitted us for the first time to conduct a detailed
comparison of the functional effects of receptor clustering,
initiated from within the cell, with the effects of increasing
integrin affinity through conformational changes. The ma-
jor conclusions of this work are: (
 
a
 
) Conformational changes
play a predominant role in 
 
a
 
IIb
 
b
 
3
 
 activation in CHO cells,
as monitored by ligand binding and cell adhesion assays.
(
 
b
 
) Clustering causes a modest increment in reversible and
ultimately irreversible binding of multivalent ligands to
 
a
 
IIb
 
b
 
3
 
, and this binding is additive to that caused by affin-
ity modulation. (
 
c
 
) Ligand binding resulting from receptor
clustering is dependent on cellular metabolic energy and is
sensitive to some, but not all, of the mutations or deletions
in the 
 
b
 
3
 
 cytoplasmic tail that block affinity modulation of
the receptor. (
 
d
 
) Integrin clustering promotes ligand-inde-
pendent tyrosine phosphorylation of Syk, and ligand-
dependent phosphorylation of FAK, even when cells are
maintained in suspension and even in the absence of delib-
erate affinity modulation. Thus, by being able to manipu-
late integrin clustering and affinity separately and in a con-
Figure 4. Effect of the dimerizer, AP1510, and the activating an-
tibody, anti–LIBS6 Fab, on PAC1 binding to CHO cells express-
ing aIIb(FKBP)2b3. Cells were transfected with aIIb(FKBP)2 and
b3. After 48 h, they were incubated for 30 min with PAC1 along
with AP1510 and/or 150 mg/ml anti-LIBS6. Then PAC1 binding
to aIIb(FKBP)2b3-expressing cells was quantitated by flow cytom-
etry as described in Materials and Methods. Specific PAC1 bind-
ing was defined as binding inhibitable by 10 mM integrilin, a se-
lective aIIbb3 antagonist. It was expressed relative to the amount
of integrin per cell determined simultaneously with antibody D57.
Figure 5. Relative effects of aIIbb3 clustering and affinity modula-
tion on the binding of multivalent PAC1 IgM and monovalent
PAC1 Fab to CHO cells. Cells stably expressing aIIb(FKBP)2b3
were incubated with a saturating concentration of PAC1 IgM
(40 nM) or recombinant PAC1 Fab (30 nM) for 30 min in the ab-
sence or presence of AP1510, and specific binding of PAC1 was
quantitated by flow cytometry. Unlike most other experiments,
PAC1 was expressed here simply as mean fluorescence intensity
in arbitrary units since correction for the degree of integrin ex-
pression was not necessary. Data represent the means 6 SD of
triplicate values from one experiment representative of two so
performed.
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trolled manner, we conclude that these two processes play
complementary roles in the function of aIIbb3.
Integrin Clustering and Inside-Out Signaling 
Inside-out signaling is responsible for acute regulation of
the ligand binding function of integrins. In the case of inte-
grins that normally engage soluble adhesive ligands in
vivo, such as aIIbb3, inside-out signaling can be monitored
directly using labeled ligands or ligand-mimetic antibod-
ies, such as PAC1. Alternatively, it can be assessed by cell
adhesion assays. Although physiologically relevant, cell
adhesion is a more indirect measure of integrin activation
because it can be influenced by factors, such as actin poly-
merization, cell spreading, and focal adhesion turnover,
that may affect the overall strength of the adhesion pro-
cess through mechanisms other than regulation of ligand
binding (Burridge and Chrzanowska-Wodnicka, 1996; Ya-
mada and Geiger, 1997; Hall, 1998). Thus, when possible,
it is preferable to monitor inside-out signaling by ligand
binding assays, as in the current study.
Ligand binding to integrins is thought to be regulated by
a combination of affinity and avidity modulation (van
Kooyk and Figdor, 1993; Diamond and Springer, 1994;
Bazzoni and Hemler, 1998). In the case of aIIbb3, platelet
activation is believed to cause a modification of the con-
formation or orientation of the integrin cytoplasmic tails
that is transmitted across the membrane, leading to in-
creased access of the ligand to binding sites in the receptor
(Loftus and Liddington, 1997; Shattil et al., 1998). How-
Figure 6. Effects of b3 cytoplasmic tail
mutations on PAC1 binding caused by
receptor clustering and affinity modu-
lation. CHO cells were transiently
transfected with the indicated aIIb and
b3 subunits. 48 h later, they were incu-
bated for 30 min with PAC1 along with
AP1510 and/or 150 mg/ml anti–LIBS6
Fab, and specific PAC1 binding was
quantitated by flow cytometry. Note
the almost 10-fold difference in scales
of the y axes. Data represent the means
6 SEM of three experiments.
Figure 7. Relative effects of receptor clustering
and affinity modulation on PAC1 binding to
aIIbb3. CHO cells were transiently transfected
with the indicated integrin constructs. 48 h later,
they were incubated for 30 min with PAC1 along
with AP1510 and/or 150 mg/ml anti–LIBS6 Fab,
and specific PAC1 binding was quantitated by
flow cytometry. Note the difference in scales of
the y axes. Data represent the means 6 SEM of
three to five experiments.The Journal of Cell Biology, Volume 141, 1998 1692
ever, cell activation appears to promote ligand binding to
certain b1 and b2 integrins by also stimulating the lateral
diffusion and clustering of these receptors (van Kooyk and
Figdor, 1993; Kucik et al., 1996; Bazzoni and Hemler,
1998; Shattil et al., 1998), and the same might be true for
aIIbb3. Several experimental approaches have been used to
cluster integrins, including treatment of cells with multiva-
lent antibodies or chemical cross-linkers, incubation of cells
with ligand-coated beads, and promotion of cell spreading
(Kornberg et al., 1991; Dorahy et al., 1995; Hotchin and
Hall, 1995; Miyamoto et al., 1995). Whereas each of these
has provided important information about outside-in sig-
naling, none is entirely suitable for studies of soluble
ligand binding to aIIbb3. The use here of AP1510 to cluster
aIIb(FKBP)b3 or aIIb(FKBP)2b3, while CHO cells were
maintained in suspension demonstrates unambiguously
that affinity and avidity modulation can complement one
another with respect to the control of ligand binding.
Given the wide variety of soluble, matrix- and cell-associ-
ated ligands that integrins must contend with, it is likely
that the relative contributions of affinity and avidity mod-
ulation will vary with the integrin and the cell type.
Fortunately, the fusion of single or tandem FKBP re-
peats to the aIIb cytoplasmic tail did not interfere with aIIbb3
expression or function in CHO cells. Perhaps this means
that the very COOH terminus of the a subunit is dispens-
able for the integrin functions that were assessed. On the
other hand, direct attachment of FKBP to the b3 tail inter-
feres with energy-dependent affinity modulation of aIIbb3,
possibly by disrupting necessary interactions of the b3 tail
with regulatory proteins (Hato, T., and Shattil, S.J., un-
published observations). We ascribe any functional effects
of AP1510 on aIIb(FKBP)b3 and aIIb(FKBP)2b3 to recep-
tor clustering. Although the evidence for this is strong, it is
largely indirect. First, AP1510 only affected those forms of
aIIbb3 that contained FKBP repeats (Figs. 6 and 7). Sec-
ond, confocal microscopy showed that AP1510 treatment
was associated with the appearance of coarse patches of
integrin staining in the surface membrane (Fig. 3). Finally,
AP1510 caused binding of a multivalent but not monova-
lent form of PAC1, precisely what might be expected in
Figure 8. Effect of receptor clustering on reversible and irrevers-
ible ligand binding to aIIb(FKBP)2b3. Binding of PAC1 in re-
sponse to anti–LIBS6 Fab was initiated in CHO cells stably-
expressing aIIb(FKBP)2b3, either in the absence or presence of
AP1510. After 10 or 30 min, half of each sample was treated with
5 mM EDTA to displace reversibly bound PAC1 and half was
not. Then specific PAC1 binding was determined. Reversible
PAC1 binding was defined as specific binding displaced by
EDTA, and irreversible binding was defined as specific binding
that was not displaced by EDTA. Data represent the means 6
SEM of three experiments.
Figure 9. Relative effects of
receptor clustering and affin-
ity modulation on CHO cell
adhesion to fibrinogen or vWF.
As described in Materials
and Methods, CHO cells sta-
bly expressing aIIb(FKBP)2b3
were fluorescently labeled
with BCECF, and then incu-
bated for 90 min in microtiter
wells coated with fibrinogen
(left panel) or vWf (right
panel) in the presence of 1,000
nM AP1510 and/or 150 mg/ml
anti–LIBS6 Fab. After wash-
ing, cell adhesion was quanti-
tated by cytofluorimetry. Ad-
hesion was expressed as a
percentage of total cells
added. This experiment is rep-
resentative of three so per-
formed. Not shown is the fact
that in the absence of AP1510,
the adhesion of aIIb(FKBP)2b3
cells was the same as for cells
expressing wild-type aIIbb3.Hato et al. Integrin Clustering and Conformation 1693
the case of integrin clustering (Fig. 5). Interestingly, the
effect of AP1510 on PAC1 binding to aIIb(FKBP)b3 and
aIIb(FKBP)2b3 was nearly equivalent (Fig. 7). Assuming
that AP1510 can only dimerize aIIb(FKBP)b3, this suggests
that formation of a dimer of dimers, e.g., (aIIb(FKBP)b3)2,
may be sufficient to initiate some ligand binding to aIIbb3.
What are the biological implications of aIIbb3 clustering
during inside-out signaling? Ligand binding resulting from
clustering of aIIb(FKBP)2b3 required a normal b3 cytoplas-
mic tail since a tail point mutation (S752P) disrupted this
process (Fig. 6). This same mutation disrupts energy-
dependent affinity modulation of aIIbb3 in CHO cells and
in human platelets, where it is responsible for a bleeding
diathesis (Chen et al., 1992, 1994). In contrast, another b3
cytoplasmic modification, a truncation starting at residue
Arg 724, did not disrupt ligand binding induced by cluster-
ing of aIIb(FKBP)2b3, although it does abolish affinity
modulation of aIIbb3 in CHO cells and platelets (O’Toole
et al., 1994; Wang et al., 1997). This suggests that there are
differences in the structural elements of the b3 tail that are
needed for affinity and avidity modulation. A growing
number of proteins have been shown to interact directly
with the cytoplasmic tails of a or b integrin subunits, at
least in vitro, and overexpression of some of them, includ-
ing calreticulin (a tails) (Coppolino et al., 1997), cyto-
hesin-1 (b2 tail) (Kolanus et al., 1996), and b3-endonexin
(b3 tail) (Kashiwagi et al., 1997) can affect ligand binding
and cell adhesion. When overexpressed in CHO cells, sev-
eral other signaling proteins, including H-ras (Hughes et
al., 1996), R-ras (Zhang et al., 1996), and CD98 (Fenczik et
al., 1997) have been shown to modulate the ligand binding
properties of aIIbb3; however, it is not known if any of
these proteins interact directly with the integrin. The rela-
tive effects of potential regulatory molecules such as these
on receptor clustering and receptor affinity remain to be
determined.
The extent of PAC1 binding observed in response to in-
tegrin clustering was only a fraction of that observed with
affinity modulation. Yet ligand binding resulting from
clustering and affinity modulation was additive (Fig. 7).
Clustering also facilitated CHO cell adhesion to immobi-
lized fibrinogen and vWf, but once again, this effect was
relatively minor compared with the effect of affinity mod-
ulation and it was apparent only at the higher coating con-
centrations of the ligands (Fig. 9). On the other hand, if
clustering of aIIbb3 were to cause increased ligand binding
in platelets as it does in CHO cells, it could affect the ulti-
mate size of a platelet aggregate and hence the delicate
balance between adequate and inadequate hemostasis or
the difference between partial and total arterial occlusion
by a platelet-rich thrombus. Conceivably, the effects of in-
tegrin clustering on ligand binding may be even more pro-
nounced in platelets than in the CHO cell model system
because receptor density may be higher in platelets and
clustering may be stimulated by agonists that trigger inte-
grin interactions with multivalent, polymerizing ligands on
both sides of the plasma membrane (Hartwig, 1992; Fox
et al., 1996; Simmons and Albrecht, 1996). Furthermore,
Figure 10. Effect of integrin clustering on tyrosine phosphorylation of Syk and FAK. In A, CHO cells stably-expressing aIIb(FKBP)2b3
were transiently transfected with Syk. 48 h later, they were incubated in suspension for 10 min as indicated with 1,000 nM AP1510, 150
mg/ml anti–LIBS6 Fab, and/or 250 mg/ml fibrinogen. Lysates were prepared and immunoprecipitated with rabbit antiserum to Syk (top)
or FAK (bottom), and samples were subjected to Western blotting with antibodies 4G10 and PY20 to phosphotyrosine (anti–P-Tyr). Fi-
nally, blots were stripped and reprobed with antibodies to Syk or FAK to assess gel loading. The first lane in each blot is a negative con-
trol using normal rabbit serum (NRS) for immunoprecipitation. The last lane (Adh) is a “positive control” in which cells were allowed to
become adherent over 60 min to immobilized antibody D57 before lysis. In B, the data represent the means 6 SEM of three such exper-
iments. The intensities of the phosphotyrosine bands are expressed relative to the intensities of the matching Syk and FAK immunore-
active bands. Asterisks denote statistically significant differences (P # 0.05) from the cells incubated in suspension without additives
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any increase in adhesive strength promoted by aIIbb3 clus-
tering in vivo might help platelets resist detachment from
sites of vascular injury in response to hemodynamic forces
(Savage et al., 1996).
Integrin Clustering and Outside-In Signaling
A potential limitation of the chemical dimerization ap-
proach used here is that it may not reflect or trigger the
types of interactions between aIIbb3, cytoskeletal proteins,
and signaling molecules that take place normally during
outside-in signaling. For example, in platelets, the binding
of fibrinogen to aIIbb3 is sufficient to trigger tyrosine phos-
phorylation and activation of Syk, whereas tyrosine phos-
phorylation of FAK requires additional post–ligand binding
events that occur during platelet aggregation or spreading
(Haimovich et al., 1993; Huang et al., 1993). In this regard,
clustering of aIIb(FKBP)2b3 in CHO cells by AP1510 caused
significant tyrosine phosphorylation of Syk, even when the
cells were maintained in suspension without fibrinogen
(Fig. 10). Since integrin-dependent tyrosine phosphoryla-
tion of Syk correlates with induction of Syk kinase activity
in both platelets and CHO cells (Clark et al., 1994; Gao et
al., 1997), these results suggest that the binding of multiva-
lent fibrinogen to aIIbb3 triggers Syk activation, at least in
part, by inducing integrin clustering.
In contrast to the results for Syk, clustering of aIIb(FKBP)2b3
by AP1510 was not sufficient to cause tyrosine phosphory-
lation of FAK in cells maintained in suspension. However,
fibrinogen binding together with receptor clustering were
sufficient to induce the response (Fig. 10). These results
highlight the apparent differences in coupling mechanisms
between aIIbb3 and Syk and aIIbb3 and FAK (Gao et al.,
1997). At the same time, they demonstrate unambiguously
that conditional clustering of aIIbb3 in CHO cells can reca-
pitulate a pattern of outside-in signaling that is character-
istic of platelets. In nucleated cells, integrin and growth
factor signaling pathways collaborate to regulate gene ex-
pression, cell adhesion, and motility (Schwartz et al., 1995;
Juliano, 1996; Sastry and Horwitz, 1996; Yamada and Gei-
ger, 1997). One hallmark of integrated signaling networks
is tight control of enzyme activity and protein subcellular
localization though regulated protein–protein interactions
(Pawson and Scott, 1997). Chemical inducers of dimeriza-
tion can be used to promote controlled homodimerization
and heterodimerization of proteins in vivo as well as ex
vivo (Rivera et al., 1996; Spencer et al., 1996; Clackson,
1997; Yang et al., 1998). Consequently, they should prove
useful in evaluating diverse aspects of integrin signaling.
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